LH 21
目录号 : GC12538Weak CB1 antagonist
Cas No.:611207-11-5
Sample solution is provided at 25 µL, 10mM.
IC50: 631 ±98 and 690 ± 41 nM for human and rat CB1 receptors, respectively
LH 21 is a CB1 antagonist.
The endogenous cannabinoid system plays a critical modulatory role in feeding behavior and metabolism, acting at both peripheral and central levels. Recently studies suggest that the chronic administration of cannabinoid CB1 receptor antagonists is effective in experimental obesity.
In vitro: Previous study showed that LH-21 was able to inhibit the binding of [3H]CP55940 to cloned human and rat CB1 receptors with IC50 values of 631 ±98 nM, and 690 ± 41 nM, respectively. LH-21 acted as an inverse agonist in a cAMP functional assay using cultured cells expressing human, rat or mouse CB1 receptor. In addition, in CHO cells overexpressing CB1, LH-21 was able to elevate cAMP, further confirming that LH-21 acted as an inverse agonist of CB1 in this model [1].
In vivo: Animal study showed that when given acutely LH-21 could decrease food intake and enhance the anorectic actions of oleoylethanolamide, a feeding suppressant lipid acting on peripheral sensory terminals in a similar way as rimonabant. However, unlike rimonabant, chronic administration of LH-21 at 3 mg/kg was able to reduce feeding but did not improve hypercholesterolaemia or hypertriglyceridaemia; nor did it reduce liver fat deposits in Zucker rats [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Chen, R. Z.,Frassetto, A.,Lao, J.Z., et al. Pharmacological evaluation of LH-12, a newly discovered molecule that binds to cannabinoid CB1 receptor. European Journal of Pharmacology 584, 338-342 (2008).
[2] Pavón, F. J.,Serrano, A.,Pérez-Valero, V., et al. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: Effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. Journal of Neuroendocrinology 20, 116-123 (2008).
Cas No. | 611207-11-5 | SDF | |
化学名 | 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole | ||
Canonical SMILES | CCCCCCC1=NN(C2=CC=C(Cl)C=C2Cl)C(C3=CC=C(Cl)C=C3)=N1 | ||
分子式 | C20H20Cl3N3 | 分子量 | 407.1 |
溶解度 | ≤10mg/ml in ethanol;10mg/ml in DMSO;10mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.4564 mL | 12.282 mL | 24.564 mL |
5 mM | 0.4913 mL | 2.4564 mL | 4.9128 mL |
10 mM | 0.2456 mL | 1.2282 mL | 2.4564 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet